ANAngus N. R. Nedderman

Angus N. R. Nedderman

*This is an algorithmically generated author record based on publicly available information.

Angus N. R. Nedderman has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • From definition to implementation: a cross-industry perspective of past, current and future MIST strategies

    by Angus N.R. Nedderman, Gordon J. Dear, Stephanie North, R. Scott Obach, David Higton

    The article describes and discusses the evolution of strategies to characterize metabolites in support of safety studies over the last 40 years, as well as future trends. Approaches to derive qualitative and quantitative information on metabolites are described, with a particular focus on the comparison of options to quantify metabolites in the absence of authentic standards. Current strategies to assess metabolite profiles are summarized into four general approaches and compared against a number of key criteria. Potential future strategies are discussed, including the use of clinical samples as the starting point for metabolite investigations, minimizing the need for animal radiolabelled studies and establishing metabolite safety without radiolabelled studies in animals or human.


  • Metabolite Testing in Drug Development

    by Angus N. R. Nedderman, Don K. Walker


  • Open Access

    Metabolites in safety testing: metabolite identification strategies in discovery and development

    by Angus N. R. Nedderman

    The publication of the FDA MIST guidelines in 2008, together with the acknowledged importance of metabolism data for the progression of novel compounds through drug discovery and drug development, has resulted in a renewed focus on the metabolite identification strategies utilised throughout the pharmaceutical industry. With the plethora of existing and emerging technologies available to the metabolite identification scientist, it is argued that increased diligence should be applied to metabolism studies in the early stages of both drug discovery and drug development, in order to more routinely impact chemical design and to comply with the concepts of the MIST guidance without re‐positioning the definitive radiolabelled studies from there typical place in late development.Furthermore, these strategic elements should be augmented by a broad and thorough understanding of the impact of the derived metabolism data, most notably considerations of absolute abundance, structure and pharmacological activity, such that they can be put into proper context as part of a holistic safety strategy.The combination of these approaches should ensure a metabolite identification strategy that successfully applies the principles of the MIST guidance throughout the discovery/development continuum and thereby provides appropriate confidence in support of human safety. Copyright © 2009 John Wiley & Sons, Ltd.